HomeFinanceEarnings and valuation of Akero Therapeutics Inc. (AKRO) Stock are impressive

Earnings and valuation of Akero Therapeutics Inc. (AKRO) Stock are impressive

Evercore ISI raised the price target for the Akero Therapeutics Inc. (NASDAQ:AKRO) stock from “an In-line” to “an Outperform”. The rating was released on September 14, 2022, according to finviz. The research report from BofA Securities has initiated the stock to Buy, with a price target set at $40. The stock was initiated by Guggenheim, who disclosed in a research note on February 26, 2021, to Buy and set the price objective to $54. In their research brief published September 10, 2020, Morgan Stanley analysts initiated the Akero Therapeutics Inc. stock to Overweight with a price target of $70.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Akero Therapeutics Inc. (NASDAQ:AKRO) raised 3.46% to close Wednesday’s market session at $45.39, higher as compared to yesterday’s close. The stock price fluctuated between $43.225 and $45.46 throughout the trading session with the volume trading being 458301 shares, which represented a significant variation when compared to the three months average volume of 1.52 million shares. The firm’s stock price fluctuated -0.77% within the last five trades and 3.32% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 454.89% in the last 6 months and 248.89% was added to its value over the previous 3 months. AKRO stock is trading at a margin of 8.32%, 21.41% and 142.96% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

As of the close of trading, AKRO deals in the Healthcare domain. The stock is trading -2.38 percent below its 52-week high and 503.59 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 4.2. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Akero Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $2.14 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 5.11, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Rolph Timothy, the Chief Scientific Officer at Akero Therapeutics Inc. (AKRO) has sold 3,947 shares of firm on Nov 16 at a price of $45.47 against the total amount of $0.18 million. In another inside trade, Rolph Timothy, Chief Scientific Officer of Akero Therapeutics Inc. (NASDAQ:AKRO) sold 3,138 shares of the firm on Nov 15 for a total worth of $0.14 million at a price of $45.04. An inside trade which took place on Nov 10, Chief Development Officer of Akero Therapeutics Inc. Yale Catriona sold 5,000 shares of firm against total price of $0.2 million at the cost of $39.42 per share.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Recent Post

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam

385

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.